Sirius Medical secures a €12 million funding round to accelerate sales growth and product development

Sirius Medical, a surgical marker navigation company from Eindhoven, the Netherlands, closed a Series B Round of €12 Million. The funding aims to accelerate the worldwide growth of their product Pintuition and support further product development. Holland Capital was the lead investor for this series B with support from existing investors BOM Brabant Ventures, Curie Capital, Team Holmium, and Sirius Medical’s management and team. Norgine Ventures joined as a new investor in this round to support the further commercial roll-out.

With its roots in the Netherlands Cancer Institute, Sirius Medical is dedicated to improving care for cancer patients by delivery of affordable solutions that enable precise and efficient removal of tumors. The Pintuition technology is both CE-marked and FDA-cleared. 

Accurately

Sirius’ navigation system Pintuition provides surgeons with real-time distance and directional navigational guidance to locate tumors easily and accurately. With over 100 active centers and over 5,000 successful Pintuition procedures across Western Europe and the US, the company experienced growth in revenue in 2022.

“Sirius Medical has done a great job developing and bringing to market the Pintuition technology with a strong commercial start”, says Peter Stein, Chief Executive of Norgine Ventures. “Norgine Ventures is excited to support Sirius Medical’s leadership and their vision to deliver cost-effective solutions in surgery.”

“We are excited about the market potential for surgical marker navigation,” says Jan Frens van Giessel, partner at Holland Capital. “We believe that the Pintuition technology and its future innovations will significantly improve surgery of non-palpable tumors for patients, physicians and improve the care for cancer patients.” 

Across the globe

“Having become the fastest growing company in the industry is a clear confirmation of the benefits that our technology brings to both patients and physicians,” says Bram Schermers, CEO at Sirius Medical.  “Supported by this latest funding round, I am confident that our team will further drive the adoption of Pintuition across the globe.”

Clinical tests show the effect and safety of Sirius Pintuition in breast cancer surgery

Initial clinical studies show that Sirius Pintuition is safe and effective in breast cancer surgery, the Eindhoven based company says. The study was conducted by … Continued